Acetazolamide for Treatment Resistant Schizophrenia
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-55
SponsorVishwajit Nimgaonkar, MD PhD
About this trial
This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.
Eligibility criteria
Qualifiers
Written informed consent.
Both genders, ages 18-55 years (older patients may not tolerate high ACZ dose).
PANSS total score > 60 and Score > 4 on one or more items of the 'positive' syndrome items (P1-P7), following treatment at therapeutic doses for 6 weeks with different APDs on 2 occasions.
Stable dose of antipsychotic drug (APD) for > 1 month, continued throughout the study.
Disqualifiers
Substance abuse in the past month/dependence past 6 months with the exception of methadone prescribed for opiate withdrawal.
History or current medical/neurological illnesses that may lead to unstable course, e.g., epilepsy.
Pregnancy.
Acetazolamide (ACZ) contraindications: hypersensitivity to ACZ; history of renal hyperchloremic acidosis; Addison's disease/adrenal failure; chronic closed angle-closure glaucoma.
Trial design
Treatments tested in this trial
- Acetazolamide
- Placebo
Treatment groups
60 Participants
are divided into 2 treatment groupsLocations
2India
St John's Medical College Hospital Bangalore India
United States
University of Pittsburgh15213, PittsburghPennsylvania, United States
Sponsors and collaborators
Vishwajit Nimgaonkar, MD PhD
Lead sponsor
University of Pittsburgh
Sponsor institution
Stanley Medical Research Institute
Collaborator
Source ClinicalTrials.gov